Ocrevus vs Kesimpta: Choosing Between Infusion Center and Home Injection for MS

Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) are both anti-CD20 monoclonal antibodies approved for relapsing forms of multiple sclerosis (MS). They work through the same core mechanism — targeting B cells that drive MS inflammation — but differ sharply in how they are administered: Ocrevus requires an IV infusion at a clinic every six months, while Kesimpta is a once-monthly self-injection given at home.

The Clinic-or-Couch Question

For many people living with MS, the conversation with their neurologist eventually lands on anti-CD20 therapy. And then comes a question that has very little to do with molecules and everything to do with daily life: Do you want to go to an infusion center twice a year, or would you rather give yourself a shot at home once a month?

This is not a trivial preference. It shapes how treatment fits around work schedules, childcare, travel plans, and emotional well-being. Some patients find comfort in the clinical setting — a nurse watching over them, a built-in health checkpoint. Others dread the half-day commitment and the planning it demands. Neither feeling is wrong.

How Both Drugs Work

Ocrevus and Kesimpta both belong to a class called anti-CD20 monoclonal antibodies. CD20 is a protein found on the surface of B cells, a type of white blood cell. In MS, certain B cells contribute to the immune system’s mistaken attacks on the myelin sheath — the protective coating around nerve fibers.

Both drugs latch onto CD20 and mark those B cells for destruction. The result is a significant reduction in MS disease activity, including fewer relapses and slower disability progression.

Efficacy Comparison

Head-to-head trial data directly comparing Ocrevus and Kesimpta do not currently exist. However, both drugs have shown strong efficacy in their respective clinical trials against active comparators.

• Ocrevus demonstrated a 46-47% reduction in annualized relapse rate compared to interferon beta-1a in the OPERA I and OPERA II trials.
• Kesimpta showed a 50.5-58.5% reduction in annualized relapse rate compared to teriflunomide in the ASCLEPIOS I and II trials.

Because they used different comparators, these numbers cannot be directly compared. Most MS specialists consider the two drugs to be roughly equivalent in efficacy. Real-world registry data have reinforced this, showing similar rates of relapse suppression and MRI activity.

One nuance worth noting: Kesimpta may achieve B-cell depletion slightly faster after the first dose due to its loading schedule (weekly injections in the first month), which some neurologists see as an advantage for patients switching from a less effective therapy.

Administration and Convenience

Ocrevus

• Given as an IV infusion at a clinic or home infusion setting
• First dose is split into two infusions, 14 days apart (300 mg each)
• Subsequent doses: 600 mg every six months
• Each infusion takes approximately 2.5–3.5 hours, plus observation time
• Pre-medication with corticosteroids and antihistamines is standard to reduce infusion reactions

Kesimpta

• Self-administered subcutaneous injection using a prefilled Sensoready autoinjector pen
• Loading doses: 20 mg weekly at weeks 0, 1, and 2, followed by a week off
• Maintenance: 20 mg once monthly starting at week 4
• Injection takes about 15 seconds
• No pre-medication required; no observation period

Side Effects

Because both drugs deplete B cells, they share certain risks:

• Infections: Increased susceptibility to upper respiratory infections, urinary tract infections, and, rarely, serious infections like progressive multifocal leukoencephalopathy (PML)
• Reduced vaccine response: Live vaccines should be avoided; inactivated vaccines may be less effective during treatment
• Low immunoglobulin levels: Prolonged B-cell depletion can reduce antibody production over time, which is monitored through periodic blood work

Where they differ is in administration-related reactions:

• Ocrevus: Infusion-related reactions (throat irritation, flushing, headache, drop in blood pressure) occur in about 34-40% of patients, mostly during the first infusion, and are managed in-clinic with the pre-medications
• Kesimpta: Injection-site reactions (redness, pain, swelling) and systemic injection reactions (fever, headache, muscle pain) occur in about 20% of patients, typically with early doses, and usually resolve on their own

Cost and Insurance

Both drugs carry high list prices, though actual out-of-pocket costs vary widely depending on insurance:

• Ocrevus: List price is approximately $65,000–$70,000 per year. Because it is infused, it is often covered under the medical benefit (not pharmacy benefit), which can mean different copay structures.
• Kesimpta: List price is approximately $85,000–$90,000 per year. Covered under the pharmacy benefit, which means it goes through specialty pharmacy channels and may have different copay requirements.

Both manufacturers offer copay assistance programs that can reduce costs to $0–$5 per dose for commercially insured patients. For Medicare patients, these programs do not apply, and assistance through foundations or state programs may be needed.

A detail many patients miss: Ocrevus infusion costs also include the facility fee charged by the infusion center, which can add hundreds or thousands of dollars. This is sometimes a separate bill. Kesimpta avoids facility fees entirely, which can make the total cost comparison closer than list prices suggest.

Switching Between Ocrevus and Kesimpta

A growing number of MS patients are switching from Ocrevus to Kesimpta, often motivated by the convenience of home injection. This transition is generally considered straightforward because both drugs target CD20.

Most neurologists recommend starting Kesimpta roughly six months after the last Ocrevus infusion, aligning with when the next Ocrevus dose would have been due. Blood work to check B-cell levels and immunoglobulin counts is typically done before the switch.

It is also possible — though less common — to switch from Kesimpta to Ocrevus, for example if a patient develops difficulty with self-injection or prefers less frequent dosing.

Quick Comparison Table

How to Decide

There is no universally “better” option. The right choice depends on a combination of medical factors and personal circumstances:

• Primary progressive MS (PPMS): Ocrevus is the only anti-CD20 therapy with an FDA indication for PPMS. Kesimpta is not approved for this form.
• Preference for fewer dosing events: Ocrevus means two clinic visits per year versus twelve injections per year with Kesimpta.
• Preference for autonomy: Kesimpta puts the patient fully in control of their treatment schedule.
• Needle anxiety: Some patients handle a monthly autoinjector pen better than an IV; others are the opposite. Neither reaction is unusual.
• Access to infusion centers: Patients in rural areas or those with long commutes may find Kesimpta more practical. Home infusion for MS therapies like Ocrevus is sometimes available but depends on the insurer and local providers.

Whatever the decision, both medications represent a major advance in MS treatment. The existence of two highly effective anti-CD20 options with very different delivery models is genuinely good news — it means the treatment can be shaped around the patient’s life, not the other way around.